Pes of neuroendocrine carcinoma where there’s proof of benign neuroendocrine tumors these precursor lesions are exceptionally uncommon inside the breast. On the case reports published so far, only a single has described a tumor with co-existing NECB and neuroendocrine cell hyperplasia [47]. Kawasaki et al. has also described that neuroendocrine ductal carcinoma in situ (DCIS) could possibly be deemed a pre-invasive stage of NECB [56]. NeuroendocrineTable 1 Summary of principal neuroendocrine carcinoma with the breast cases published inside the indexed literature (n=83)aNeuroendocrine IHC Author (year) [Ref] Wade (1983) [18] Jundt (1984) [16] Papotti (1992) [19] Age (years)/Sex 52/F 52/M 64/F 41/F 41/F 69/F Papotti (1993) [17] Francois (1995) [20] Chua (1997) [21] Fukunaga (1998) [22] Samli (2000) [23] Shin (2000) [24] 83/M 68/F 45/F 56/F 60/F 43/F 44/F 46/F 50/F 51/F 57/F 62/F 64/F 70/F Yamasaki (2000) [25] Salmo (2001) [26] Zekioglu (2003) [27] 41/F 46/F 79/F 76/F 65/F 68/F 69/F 72/F 60/F 43/F Internet site R R R L L L R R L R L R L R R R L L L L R R R L R R R R R L Size (cm)b ten.0 NS 2.0 3.five 3.0 five.0 1.5 4.5 NS 10.0 8.0 1.three two.0 three.four two.2 1.five 2.5 five.0 1.eight 4.0 4.five four.0 1.5 2.two three.five 7.0 1.0 1.five 1.0 0.eight TNM T4N1M0 TxN1M0 T1N0M0 T2NxM0 T2NxM0 T3NxM0 T1N0M0 T2N0M0 T2N0Mx T3NxM0 T4N1M0 T1NxM0 T1NxM0 T2NxM0 T2NxM0 T1NxM0 T2NxM0 T3NxM0 T1NxM0 T2NxM0 T2N0M0 T2N0M0 T1N0M0 T2N0M0 T2N0M0 T3N1M0 T1N0M0 T1N0M0 T1N0M0 T1N0M0 IS NS + + + + + NS NS + NS NS NS NS + NS NS + NS + + + + + + + + + + + + NS + + + + + + + + + + + + + + + + + + NS + + + + + NS + + + + + + + NS NS NS GML NSE CgA/B Syn NSG + + + + + + + + + + + NS + + NS + + NS + + + + + + Hormonal receptors ER NS NS + NS NS NS NS NS NS NS NS NS NS NS + + + + + + + PR NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS + + + + + + + + HER2/Neu Neoadjuvant NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS Ch Ch NS NS NS NS NS NS NS NS Therapy Surgical Mast/ALND NS Mast/ALND Mast/ALND Mast/ALND Mast/ALND Mast Mast/ALND BCS Mast/ALND Mast/ALND BCS BCS/ALND Mast/ALND BCS/ALND BCS/ALND Mast/ALND Mast/ALND BCS/ALND BCS/ALND BCS/Mast/ALND BCS Mast/ALND BCS Mast/ALND Mast/ALND Mast/ALND BCS BCS BCS Adjuvant Follow-up Outcome (months) Ch Ch/RT NS RT Ch HT NS RT NS Ch/RT RT Ch/RT Ch Ch/HT RT Ch Ch/HT Ch Ch/RT Ch Ch/RT NS NS NS NS NS NS NS NS 9 14 44 15 14 9 84 21 NS 48 6 30 27 11 35 25 10 32 ten 3 16 9 24 18 16 22 12 13 10 48 DOD DOD NED DOD LR/DOD DOD DOD D-NOS NS NED LR NED NED AWM NED NED NED AWM NED NED NED NED NED NED NED NED NED NED NED NEDAngarita et al. Globe Journal of Surgical Oncology 2013, 11:128 http://www.wjso/content/11/1/128 Web page four ofTable 1 Summary of major neuroendocrine carcinoma of your breast cases published within the indexed literature (n=83)a (Continued)60/F 43/F 72/F 72/F Bergman (2004) [28] Bigotti (2004) [29] Jochems (2004) [30] Sridhar (2004) [31] Yamamoto (2004) [32] 61/F 56/F 71/F 58/F 53/F 75/F Berruti (2004) [33] Adegbola (2005) [34] 59/F 46/F 60/F 61/F Valdes (2006) [35] Fujimoto (2007) [36] Kim (2008) [37] Kinoshita (2008) [9] Stita (2009) [38] Yamaguchi (2009) [39] Christie (2010) [40] Latif (2010) [41] Honami (2011) [42] 41/F 40/F 27/F 31/F 64/F 51/F 61/F 53 /F 54/F L L L L L L NS R NS NS NS R R L R/MF L/MF L L L R L R B 2.Anti-Mouse PD-1 Antibody 5 five.HO-1 Protein, Human 0 2.PMID:24455443 7 two.7 2.five 18.0 three.0 two.0 six.five two.0 NS 1.0 1.7 1.7 1.five two.0 three.2 six.0 three.0 3.0 three.0 six.0 L: 1.0 R: 1.five Kawanishi (2011) [43] Nozoe (2011) [44] Zhang (2011) [45] 67/F 57/F 29/F R R B 0.eight 3.0 L: eight.5 R: 2.0 Su (2012) [46] Miura (2012) [47] Kawasaki (2012) [4.
